Voloridge Investment Management
KRYS icon

Voloridge Investment Management’s Krystal Biotech KRYS Stock Holding History

Voloridge Investment Management’s Portfolio KRYS Stock Details KRYS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-5,044
Closed -$585K – 1324
2023
Q3 		$585K Sell
5,044
-11,006
-69% -$1.34M ﹤0.01% 1188
2023
Q2 		$1.88M Buy
+16,050
New +$1.64M 0.01% 998
2022
Q1 		– Sell
-26,517
Closed -$1.85M – 1553
2021
Q4 		$1.85M Buy
+26,517
New +$1.54M 0.01% 1102
2021
Q3 		– Sell
-5,604
Closed -$381K – 1755
2021
Q2 		$381K Buy
+5,604
New +$391K ﹤0.01% 1483
2020
Q2 		– Sell
-4,800
Closed -$208K – 1390
2020
Q1 		$208K Sell
4,800
-1,306
-21% -$68.3K 0.01% 942
2019
Q4 		$338K Buy
+6,106
New +$300K 0.01% 903

Other funds holding KRYS

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Lord, Abbett & Co
Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

Voloridge Investment Management's KRYS Position: Q4 2023 in Review

Voloridge Investment Management sold out of Krystal Biotech (KRYS) in Q4 2023, closing a stake of 5,044 shares — an estimated $585K sold.

Voloridge Investment Management first reported a position in KRYS in Q4 2019 and held it in 6 quarters. The position peaked at $1.88M in Q2 2023. 194 funds tracked by Wall St. Rank hold KRYS as of Q4 2023.

  • Voloridge Investment Management reported no remaining Krystal Biotech position as of Q4 2023 after selling out during the quarter.
  • Voloridge Investment Management sold 5,044 Krystal Biotech shares in Q4 2023, an estimated $585K.
  • Voloridge Investment Management first reported a position in Krystal Biotech in Q4 2019 and held it in 6 quarters.
  • Voloridge Investment Management's Krystal Biotech position peaked at $1.88M in Q2 2023.
  • 194 funds tracked by Wall St. Rank held Krystal Biotech as of Q4 2023.

Based on Voloridge Investment Management's 13F filing for Q4 2023, filed 14 Feb 2024.